_edited.png)
How Foreign Cannabis Companies Can Enter the Indian Market: A 2026 Market-Entry Guide
By Delta Botanicals & Research · Last updated: 30 September 2026
This article is for general information and is not legal advice. Cannabis and hemp rules in India depend on the product, the activity and the state. Get advice specific to your products before committing capital.
Key takeaways
India is not one cannabis market. It is several different regulatory markets sharing one plant.
Your first question should not be "Can we sell this in India?" It should be "What does India legally consider this product to be?"
Compliance in the US, EU, UK, Canada or Australia does not transfer to India.
Importing a finished product and manufacturing locally are different regulatory problems. The first is not automatically the easier one.
Classify your products SKU by SKU before choosing a partner, signing a distribution agreement or shipping samples.
A typical enquiry reaches us like this. A foreign company sends a catalogue of dozens of products, certificates from its home market and a single line: "We want to launch these products in India."
It is a reasonable ambition and a very large market. It is also the wrong place to start.
The catalogue assumes that India is one market with one set of rules, and that the only question is distribution. It is not, and it isn't.
India Is Not One Cannabis Market
The same plant sits under several separate regulatory frameworks in India, depending on which part of it you use, what you make from it and what you say it does. In practice, a foreign catalogue usually spans several of these:
The "market" inside India | What defines it | Main regulator or framework to ask about first |
Hemp-seed foods | Seed, seed oil and seed flour meeting defined conditions | FSSAI hemp-seed framework |
Ayurvedic cannabis formulations | Vijaya/Bhanga-based ASU medicines | Ministry of Ayush, state licensing authorities |
Topicals and personal care | Ingredient status and the cosmetic-versus-drug line | Cosmetics and drug rules |
Pharmaceutical-grade cannabinoid products | Drug status and approvals | CDSCO and drug rules |
Industrial hemp (fibre, seed, biomass) | Cultivation permissions granted by states | State governments |
Flower, resin and controlled material | NDPS Act controls | Central and state NDPS authorities |
A single catalogue can contain products from four or five of these rows. Each row has different entry conditions, and some products will not have a lawful route into India at all.
That is why the first question is not "Can we sell this?" It is: What does India legally consider this product to be?
The Classification Chain: From Product to Shelf
We take every product through the same sequence. Skipping a step is how companies end up with stock they cannot sell.
Product → Ingredient → Plant part → Classification → Import or local manufacture → Regulator → Claims → Distribution
1. Product
Start with what the product actually is: format, dose form, strength, intended user and intended use. "CBD oil" describes a category of marketing, not a legal product. A 30 ml oral oil, a topical balm and a capsule can each land in a different framework.
2. Ingredient
List every ingredient, not just the headline cannabinoid. What is the cannabinoid source: isolate, distillate, full-spectrum extract or whole-plant material? What else is in the formula?
3. Plant part
This is where India differs most from many export markets. Under the NDPS Act, the definition of "cannabis" is built around resin and the flowering or fruiting tops. Seeds, and leaves when not accompanied by the tops, fall outside that definition.
Even the Union government's own submissions in the Delhi High Court draw a distinction between the fibre, the flower and the seed, and note that Bhang is not controlled under the NDPS Act but by state governments.
That does not mean seeds or leaves are unregulated. It means the plant part determines which rules apply. A CoA showing low THC does not answer this question. Legal category depends on source and what the product is, not on a lab number alone.
4. Classification
Only now can you ask what category the finished product falls into: food, Ayurvedic drug, cosmetic, drug or something that has no lawful consumer route. There is no single "CBD licence" in India.
See our guide to hemp licence vs cannabis licence in India and the fuller explainer on cannabis laws in India.
5. Import or local manufacture
These are different regulatory questions, and each has its own conditions:
Route | What it involves | Where it usually gets stuck |
Import the finished product | Import clearance for the product's category | Some cannabis-derived material may not be importable at all; NDPS import and export are tightly controlled |
Manufacture locally under licence | A licensed Indian manufacturer for that category | Finding a manufacturer whose licence actually covers your product |
License your formula or brand to an Indian manufacturer | IP, technology transfer, quality agreement | Formula ownership and control of quality |
Supply an ingredient to Indian manufacturers | Lawful import or local sourcing of the ingredient | Import permission for the specific material |
Partner with an Indian brand | Distribution or co-development | Aligning the partner's licences with your product |
Do not assume the finished-product import is the easy option. For many cannabinoid products, local manufacture under an Indian pathway is the realistic route.
6. Regulator
Depending on the product, you may deal with FSSAI, the Ministry of Ayush and state licensing authorities, CDSCO, state governments and NDPS authorities. Customs and trade rules apply to anything crossing the border. Which of these matters is a result of classification, not a choice.
7. Claims
What you may say about a product is regulated separately from what it contains. Health and therapeutic claims that are routine in your home market may not be permissible here. Advertising and label rules differ by category, and imagery matters as well as words. FSSAI's hemp-seed framework, for example, restricts CBD claims and cannabis imagery on qualifying hemp foods.
8. Distribution
Only at the end do channels matter: direct-to-consumer, marketplaces, distributors, pharmacies or practitioner channels. A product's category can restrict which channels are open. A local importer of record, distributor agreements and trademark protection in India all need to be planned, not assumed.
What Is Moving in 2026
Three developments matter for anyone planning entry.
A court-ordered policy review. On 23 January 2026, in Great Legalisation Movement India Trust v. Union of India, the Delhi High Court did not change the law. It directed the Union government to run a stakeholder consultation on whether the NDPS Act and Rules need to be diluted for cannabis use, and for what purposes. It set a six-month window for a decision and allowed the petitioner to revive the case if none was taken. We have not found a published policy decision as of 30 September 2026. Treat this as something to watch, not something to plan around.
Central clearance for Bhang-containing Ayurvedic drugs. In August 2024 the Ministry of Ayush directed state and UT licensing authorities to grant manufacturing licences for ASU drugs containing Bhanga, Ganja, Charas or Bhang (except seed) only after clearance from the Central Government. Existing licences and pending applications were to be sent to the Ministry for review. See our guide to Ayurvedic cannabis products in India.
Revised ASU manufacturing rules. Trade reports say the Ministry of Ayush notified wide-ranging amendments to the Drugs Rules, 1945 in July 2026, covering ASU manufacturing licences and GMP standards. Anyone relying on an Ayurvedic route should check the current rule text.
Our advice: structure entry so it works under today's rules and can expand if the rules change. Do not build a business plan that only works if cannabis policy liberalises.
Six Ways Foreign Companies Enter India, and Who Each Suits
Entry route | Best suited to | Key risk |
Hemp-seed food product (import or local) | Food and nutrition brands with qualifying hemp-seed products | Products outside the qualifying framework; label and claims restrictions |
Ayurvedic route via a licensed Indian manufacturer | Brands with a formulation that can be presented within an Ayurvedic framework | Central clearance step; formulation must fit classical or proprietary ASU definitions |
Ingredient supply to Indian manufacturers | Extract or ingredient producers | Lawful import of the specific material; sourcing documentation |
Formula or brand licensing | IP-rich companies without local operations | Loss of control over quality and formulation |
Research and development collaboration | Companies with genetics, data or clinical assets | Permissions for research use of cannabis material |
Partnering with an established Indian company | Companies needing licences and distribution | Partner's licences may not cover your products |
Catalogue Triage: How to Send Us Your Product List
The most useful thing an overseas company can do is prepare its catalogue in a form that can be classified. For each product, we need:
SKU | Format | Cannabinoid or hemp material and plant part | Source of the material | Intended use and current claims | Where sold today and under what category | Target Indian channel |
From that, the assessment returns, for each SKU: the likely Indian category, a feasible entry route, what must be resolved first and which products to set aside. It will not promise approval. Its purpose is to stop you spending money on the wrong 30 products before you have found the right five.
Seven Mistakes That Cost Overseas Companies Time and Money
Assuming home-market compliance transfers. FDA-, EU-, UK-, Canadian- or Australian-compliant does not mean India-compliant.
Shipping samples first. Do not send cannabis-derived samples to India until the import position for that material is confirmed. Small quantities may not be exempt.
Signing an exclusive distribution agreement before classification. You may lock yourself to a partner whose licences don't fit the product.
Treating India as one regulator. It is several, and they do not always agree on the same product.
Leading with the whole catalogue. Enter with the products most likely to have a lawful route.
Copying overseas claims onto Indian labels. Claims and imagery need to be reviewed per category.
Ignoring the state level. Cultivation, Bhang and some licences involve state governments, and states differ.
How Delta Works
Delta acts on the buyer's and market-entrant's side of the table. We are an advisory and R&D company and do not present ourselves as a manufacturer. Our role is to help you decide what can be brought to India, in what form and by which route, then structure the sourcing, manufacturing and launch steps that follow.
Frequently Asked Questions
Can a foreign cannabis company sell in India?
Some product categories have lawful routes and some do not. It depends on the product, its ingredients and plant part, and the pathway. Classify first.
Can I sell CBD products in India?
There is no single CBD pathway. The answer depends on the product category, the source of the cannabinoid and the claims you plan to make.
Can I import cannabis or CBD into India?
Import and export of NDPS-controlled material are tightly restricted and need central authorisation. Whether a specific extract or finished product is affected depends on what it is. Confirm before shipping anything, including samples.
Is hemp-seed oil treated the same as CBD oil?
No. Hemp-seed foods sit in a defined FSSAI framework. That framework is not a general authorisation for extracted cannabinoids.
Do my FDA, EU or UK approvals help in India?
They may help as supporting evidence of quality, but they do not create Indian approval.
Should I manufacture in India or import the finished product?
It depends on classification, permissions, economics and control of quality. For many cannabinoid products, local manufacture under a licensed Indian pathway is the more realistic route.
Do I need an Indian partner?
Usually yes, for licences, importer-of-record functions and distribution. Choose a partner whose licences cover your product category. However, there exists other pathways to establish your business in India. To know more, drop us an email to info@deltabotanicals.in
How long does market entry take?
It depends on category, permissions and partner readiness. Be cautious of anyone offering fixed timelines across categories.
Will India legalise cannabis soon?
A court has directed a policy review, but the law has not changed as a result. Plan around the rules as they stand.
Start With Your Catalogue
If you are an overseas company planning for India, send us your product list in the format above, together with your current markets and what you want to achieve. We can tell you which products have a route, which need restructuring and what to resolve before you commit capital.
Send us an email to info@deltabotanicals.in with the subject "Requesting Assessment"
Classification first. Route second. Partner third.
Related reading
Sources
Delhi High Court, W.P.(C) 7608/2019, decision dated 23 January 2026: https://delhihighcourt.nic.in/app/showFileJudgment/75523012026CW76082019_121930.pdf
Ministry of Ayush order dated 7 August 2024 on ASU drugs containing Bhang: https://tnslaim.tn.gov.in/pdf/ayush-files/ORDER_Illegal_Selling_of_Ayurveda_Siddha_and_Unani_2.pdf
Trade report on July 2026 amendments to the Drugs Rules, 1945 (ASU): https://drugscontrol.org/news-detail.php?newsid=45500 (check the Gazette of India notification of 24 July 2026 for the primary text)
Comments